20 YEARS OF PROFESSIONAL & DEDICATED SERVICE TO GLOBAL CUSTOMERS

Custom Manufacturing, Project Outsourcing, your Trusted Partner from China

Understanding DOTMA: A Key Component in Nucleic Acid Delivery Systems

The precise and efficient delivery of nucleic acids, such as DNA and RNA, is a central challenge in modern biotechnology and medicine. NINGBO INNO PHARMCHEM CO.,LTD. highlights DOTMA (1,2-di-O-octadecenyl-3-trimethylammonium propane chloride salt) as a pivotal cationic lipid that addresses this challenge effectively.

DOTMA is renowned for its role in forming cationic liposomes, which are essential for the delivery of negatively charged nucleic acids. The cationic nature of DOTMA allows these liposomes to bind strongly to nucleic acids, forming stable complexes that are protected from degradation in biological environments. This complexation is fundamental to achieving successful gene transfection and the delivery of therapeutic oligonucleotides.

The mechanism by which DOTMA facilitates delivery involves its ability to promote interaction between the liposome and the target cell membrane. The positive charge on the DOTMA-containing liposome enhances the electrostatic attraction to the typically negatively charged cell surface. This improved interaction leads to more efficient cellular uptake, whether through endocytosis or membrane fusion, ensuring that the encapsulated nucleic acids reach their intended cellular compartments. This makes DOTMA a critical element for researchers involved in various DOTMA gene transfection protocols.

Beyond research applications, DOTMA plays a crucial role in the development of advanced therapeutic agents. Its use in formulating liposomes for drug delivery, especially for encapsulating siRNAs and miRNAs, is a rapidly growing area. These formulations are being explored for a wide range of diseases, including genetic disorders and cancer. The reliability and effectiveness of DOTMA as a component in these systems make it a sought-after material for pharmaceutical innovation. NINGBO INNO PHARMCHEM CO.,LTD. is a committed manufacturer and supplier of high-quality DOTMA, supporting these critical developments.

For scientists and developers working with nucleic acid delivery systems, understanding the properties of DOTMA is key to optimizing their formulations. Its proven efficacy in promoting gene delivery and its versatility in various therapeutic applications solidify its position as an indispensable chemical intermediate in the biotechnology sector.

Manufacturing Facilities

NINGBO INNO PHARMCHEM CO.,LTD. was established in 2007. It is committed to the R&D, production and sales of raw materials, pharmaceutical intermediates and fine chemicals. We striving to create a high-efficiency and high-quality integrated chemical service platform to better serve domestic and foreign customers.

Professional Export Experience

to Global Customers

WHY CHOSE US?

1. 20 years of R&D, manufacturing and sales experience, serving customers in 60 countries and regions around the world;

2. Own R&D laboratory, pilot platform and large-scale production workshop, which can meet the audit requirements of global customers;

3. We can satisfy customers' perfect transition from small scale lab requirements (gram level) to commercialization requirements (hundred tons level).

FAQ

  • A: We don't have Minimum Order Quantity, exact quantity should be provided before quotation for us to calculate the exact cost.

  • A: We don't provide free samples due to lots of request and expensive international courier's cost, we can deduct the sample charge after commercial order placed.

  • A: Our payment terms: Small or sample order: T/T IN ADVANCE. Commercial order: First order should be by T/T IN ADVANCE or L/C at sight, and following orders T/T 30~90days is acceptable subject to approval of credit application.

CONTACT US
Should you need to contact us; you may call during regular business hours, Monday through Friday, 8am – 6 pm.
NINGBO INNO PHARMCHEM CO.,LTD.
Address: No.163 Ruiqing Rd.,Ningbo 315000 China
Phone: 86-574-87319282
Fax: 86-574-27912196
SEND US AN EMAIL

NAME*

EMAIL*

COMPANY

COUNTRY*

MESSAGE*

Previous: DOTMA: The Cationic Lipid Powering Gene Therapy and Vaccine Development

Next: Exploring the Potential of DOTMA in Targeted Cancer Therapies

All Rights Reserved